- Home
- EPIX vs GALT Comparison
EPIX vs GALT Comparison
Compare EPIX & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- GALT
- Stock Information
- Founded
- EPIX 2009
- GALT 2000
- Country
- EPIX Canada
- GALT United States
- Employees
- EPIX N/A
- GALT N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- GALT Health Care
- Exchange
- EPIX Nasdaq
- GALT Nasdaq
- Market Cap
- EPIX 75.9M
- GALT 83.5M
- IPO Year
- EPIX N/A
- GALT N/A
- Fundamental
- Price
- EPIX $1.87
- GALT $3.06
- Analyst Decision
- EPIX Hold
- GALT Buy
- Analyst Count
- EPIX 3
- GALT 2
- Target Price
- EPIX $2.00
- GALT $6.00
- AVG Volume (30 Days)
- EPIX 452.3K
- GALT 320.5K
- Earning Date
- EPIX 08-04-2025
- GALT 08-12-2025
- Dividend Yield
- EPIX N/A
- GALT N/A
- EPS Growth
- EPIX N/A
- GALT N/A
- EPS
- EPIX N/A
- GALT N/A
- Revenue
- EPIX N/A
- GALT N/A
- Revenue This Year
- EPIX N/A
- GALT N/A
- Revenue Next Year
- EPIX N/A
- GALT N/A
- P/E Ratio
- EPIX N/A
- GALT N/A
- Revenue Growth
- EPIX N/A
- GALT N/A
- 52 Week Low
- EPIX $1.40
- GALT $0.73
- 52 Week High
- EPIX $7.88
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- EPIX 63.77
- GALT 68.74
- Support Level
- EPIX $1.86
- GALT $2.54
- Resistance Level
- EPIX $1.88
- GALT $3.15
- Average True Range (ATR)
- EPIX 0.02
- GALT 0.24
- MACD
- EPIX 0.00
- GALT 0.01
- Stochastic Oscillator
- EPIX 94.74
- GALT 88.57
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.